Stay updated on Pembrolizumab for Advanced Uveal Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Advanced Uveal Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab for Advanced Uveal Melanoma Clinical Trial page
- Check6 days agoChange DetectedThe record presents details of a terminated Phase II pembrolizumab study for advanced uveal melanoma, including its study design, eligibility criteria, outcomes, locations, and investigators.SummaryDifference53%

- Check13 days agoChange DetectedThe footer’s ClinicalTrials.gov revision identifier changed from v3.7.2 to v3.8.0. The study record remains unavailable because the page displays a 403 Forbidden error.SummaryDifference0.2%

- Check27 days agoChange DetectedA site-wide NIH notice announces the transition from “Artificial Intelligence” to “Super Intelligence” terminology under Executive Order 14434. The site revision label also changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check41 days agoChange DetectedThe site footer revision marker changes from v3.7.0 to v3.7.1; the study page continues to display a 403 Forbidden message.SummaryDifference0.2%

- Check55 days agoChange DetectedThe study page now displays a 403 Forbidden error screen with a minimal header and a Home button, replacing the previous study details and navigation. This indicates an access-denied state rather than an update to the study information.SummaryDifference19%

- Check62 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing Revision: v3.6.6. This reflects a system update rather than changes to the study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Advanced Uveal Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Advanced Uveal Melanoma Clinical Trial page.